Diamyd Medical receives patent protection in the US and Japan for GABA formulation Remygen®

The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the Company’s oral formulation of the GABA-based study drug Remygen[®]. Remygen[®] is currently in Phase 2 development through the ReGenerate-1 trial in individuals with long-term Type 1 Diabetes. Results are expected later this quarter.“The ongoing phase 2 trial ReGenerate-1 will guide us on how to move forward with Remygen”, says Ulf Hannelius, CEO of Diamyd Medical. “Patent protection for the formulation is important for all possible routes forward,